Challenges in ultralong-acting formulation development: eyes on buprenorphine

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Challenges in ultralong-acting formulation development: eyes on buprenorphine ; volume:2 ; number:1 ; year:2023 ; pages:1-3 ; extent:3
NeuroImmune Pharmacology and Therapeutics ; 2, Heft 1 (2023), 1-3 (gesamt 3)

Creator: Deodhar, Suyash
Edagwa, Benson
Sillman, Brady

DOI: 10.1515/nipt-2023-0001

URN: urn:nbn:de:101:1-2023040414082825691752

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Deodhar, Suyash
Edagwa, Benson
Sillman, Brady

Other Objects (12)

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

$A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models$

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

$A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models$

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

$A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models$

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Challenges in ultralong-acting formulation development: eyes on buprenorphine

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

A platform technology for ultra-long acting intratumoral therapy

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study

Long‐Acting Microparticle Formulation of Griseofulvin for Ocular Neovascularization Therapy

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

High-dissymmetry circularly polarized ultralong phosphorescence

Ultralong Imaging Range Chromatic Confocal Microscopy

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose

Related objects

Reset password